7 things to consider before you commit to MYOB Group Ltd's shares

MYOB Group Ltd is set to hit the market on 4 May, but will its float be as successful as that of Medibank Private Ltd (ASX:MPL)? And can it compete with the likes of Reckon Limited (ASX:RKN) and XERO FPO NZ (ASX:XRO)?

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It's pretty rare that a pending initial public offering (IPO) generates a huge amount of excitement, but the float of MYOB Group Ltd's shares in May is bound to do just that. The accounting software provider will be valued between $2.3 billion and $2.7 billion which will make it the biggest float since that of Medibank Private Ltd (ASX: MPL) late last year.

The shares will be offered to retail and institutional investors at a price between $3 and $4 each and you can expect there will be plenty of mum and dad investors eager to get their hands on their fair share. However, before you commit your hard-earned savings to the rights to some of the company's shares, there are a few factors which you should seriously consider…

The Pros

  • As was the case with Medibank in November last year, MYOB could attract an enormous amount of attention from investors. Investors who participate in the IPO could make a very nice paper profit early in the game.
  • As is the case with many software providers, MYOB is protected by high costs of switching providers, leading to high retention rates. According to its prospectus, its SME (small and medium enterprises) user retention rate grew to approx. 81% in the 2014 financial year, up from 78% in 2011.
  • MYOB has set a target payout ratio of 60% to 80% of net profit after tax and amortisation (NPATA). This would indicate a dividend yield of 2.8% to 3.3% to June 2016.
  • MYOB has traditionally provided desktop-based accounting software but is making significant investments to develop its cloud-based services offering. The company said that "67% of new clients (are) choosing cloud products" while many of its non-paying desktop users are also expected to switch over to the cloud, which could help generate significant earnings growth.

The Cons

  • Rather than being provided with an exact price per share, investors have been given a range of $3 to $4 while an exact figure will be provided on 1 May (after applications for stock have closed). That means that investors could pay $3 per share (if demand for the stock is low), or 33% more if demand is high (I would expect the price to be at the upper end of the range provided). Understandably, most investors would prefer to know exactly what they're paying for before paying for it.
  • MYOB has grown strongly under Bain Capital, but it faces some strong competition from the likes of Reckon Limited (ASX: RKN) and XERO FPO NZ (ASX: XRO). Xero, which is a pure cloud-accounting software provider, is quickly gaining market share and could certainly leave MYOB behind in the coming years.
  • MYOB has also come under heavy criticism from Xero which claims that it has overstated customer numbers whilst also neglecting to mention how many cloud-based customers it has in New Zealand. As highlighted by the Fairfax press, two of MYOB's founders now sit on Xero's board, while Xero's CEO Rod Drury claims that MYOB has falsely positioned itself as a fast-growth cloud business to give Bain Capital a good exit strategy.

When a company the size of MYOB announces its plans to list on the securities exchange, it's certain to attract an enormous level of interest from the market. As exciting as the MYOB IPO might be however, it's very unlikely that I'll be taking part in the float.

As it stands, I already own shares in MYOB's rival Xero based on the belief that the pure cloud-accounting software provider could be an even more powerful force in the future, even though it is still operating at a loss right now.

Motley Fool contributor Ryan Newman owns shares in XERO FPO NZ. The Motley Fool owns shares in XERO FPO NZ. You can follow Ryan on Twitter @ASXvalueinvest.

More on ⏸️ Investing

A white and black robot in the form of a human being stands in front of a green graphic holding a laptop and discussing robotics and automation ASX shares
Technology Shares

Joining the revolution: How I'd invest in ASX AI shares right now

Advances in artificial intelligence (AI) could usher in a new industrial revolution. Here’s how you can invest in it.

Read more »

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »